May 15, 2022
Urovant Sciences® presents new data from EMPOWUR study, advancing knowledge of the treatment of overactive bladder at the 2022 American Urological Association Meeting
May 13, 2022
Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting
April 19, 2022
Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® (Vibegron) 75mg in Dry and Wet Overactive Bladder Populations
April 13, 2022
Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting
April 4, 2022
Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer
March 22, 2022
Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management
March 7, 2022
Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902